biomy Selected for METI/NEDO GENIAC Program for Generative AI Foundation Model

Key facts

  • biomy Selected for METI/NEDO GENIAC Program for Generative AI Foundation Model
  • biomy has been selected for the GENIAC project by METI and NEDO. Partnering with the Cancer Institute and UTokyo, it will develop the 'Virtual Cell' multimodal spatial AI model to accelerate next-gen drug discovery.
  • Source: PR Times
  • Date: June 4, 2026

Direct answer

biomy has been selected for the GENIAC project by METI and NEDO. Partnering with the Cancer Institute and UTokyo, it will develop the 'Virtual Cell' multimodal spatial AI model to accelerate next-gen drug discovery.

Citation
biomy Selected for METI/NEDO GENIAC Program for Generative AI Foundation Model (June 4, 2026), PR Times
Source
PR Times
Date
June 4, 2026
biomy has been selected for the GENIAC project by METI and NEDO. Partnering with the Cancer Institute and UTokyo, it will develop the 'Virtual Cell' multimodal spatial AI model to accelerate next-gen drug discovery.
businessNQ 86/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: June 4, 2026 at 23:10
  • 🔍 Collected: June 4, 2026 at 14:20
  • 🤖 AI Analyzed: June 6, 2026 at 22:07 (55h 46m after Collected)
biomy was selected for the 'Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project / Development of Competitive Generative AI Foundation Models (GENIAC)' driven by METI and NEDO. Through GENIAC, biomy will develop the 'Virtual Cell,' a foundation model that reconstructs the human tumor microenvironment computationally. This aims to identify novel target molecules, stratify patients in clinical trials, predict optimal combination therapies, and drastically improve clinical trial success rates and shorten drug development timelines. Clinical trial failures often stem from the difficulty of predicting effects on complex tumor microenvironments and behavioral differences between animals and humans. biomy tackles this by developing a model that extracts global spatial features from a single tissue section and learns complex molecular-morphological relationships. In collaboration with the Cancer Institute, biomy will build a multimodal spatial dataset integrating spatial transcriptomics, multiplex immunofluorescence, and H&E images. With technical support from the University of Tokyo, they will train a model to predict spatial gene and protein expression distributions across entire tissues under virtual interventions. The model will be evaluated with JBIC via industry-academia-government collaboration and licensed non-exclusively.

FAQ

What project was biomy selected for?

The 'Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project / Development of Competitive Generative AI Foundation Models (GENIAC)' promoted by METI and NEDO.

Who is collaborating on this project?

biomy will collaborate with the Cancer Institute Hospital of JFCR, the University of Tokyo, and the Japan Biological Informatics Consortium (JBIC).

Why develop the Virtual Cell foundation model?

To overcome the difficulty of predicting drug efficacy in complex tumor microenvironments, aiming to shorten drug development periods and improve clinical trial success rates.

When did the GENIAC project begin?

The project started in February 2024, and this is the 4th round of selections.

Where and how will the developed model be utilized?

It will be validated with JBIC through industry-academia-government collaboration, and after demonstration, non-exclusive licenses will be provided to contribute to next-generation AI drug discovery.